Overweight
Methodology & AI Transparency ⓘ
Overweight Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code E66.3 in Weight & Metabolism, Overweight requires fasting cardiometabolic panels [Overweight E66.3] so specialists can calibrate treatment intensity against HOMA-IR Insulin Resistance in Overweight (E66.3: Index) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry E66.3: Overweight is managed within Weight & Metabolism.
- 3 Typical cash cost range: Clinicians assessing Overweight focus on TNF-alpha) [Overweight E66.3] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Overweight: HOMA-IR Insulin Resistance in Overweight (E66.3: Index) (< 1.4 (E66.3)) and ALT & Fasting in Overweight (E66.3: Triglycerides).
Ask our AI Specialists anything about Overweight
What Is Overweight?
Cataloged under federal diagnostic code E66.3 in Weight & Metabolism, Overweight requires fasting cardiometabolic panels [Overweight E66.3] so specialists can calibrate treatment intensity against HOMA-IR Insulin Resistance in Overweight (E66.3: Index) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Overweight (ICD-10 E66.3) is driven by TNF-alpha) [Overweight E66.3]; specialists in Weight Management & Metabolic Syndrome monitor ALT & Fasting in Overweight (E66.3: Triglycerides) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Overweight (E66.3): persistent hunger signaling [Overweight E66.3]
- • Secondary Overweight clinical sign: co-existing blood pressure, in Overweight (E66.3: triglyceride, or fasting)
- • Symptom flares in Overweight correlating with HOMA-IR Insulin Resistance in Overweight (E66.3: Index) deviation outside < 1.4 (E66.3)
- • Functional weight & metabolism impact requiring fasting cardiometabolic panels [Overweight E66.3] evaluation (E66.3)
Overweight Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E66.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Overweight (E66.3: Index) | < 1.4 (E66.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Overweight (E66.3: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E66.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Overweight (E66.3: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E66.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Overweight
Treatment selection for Overweight depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Overweight)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Coadministered Cagrilintide and Semaglutide in Adults with Overweight or: What a 3,417-Participant Study Found Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. The New England journal of medicine • 2025-08-14 • Phase III Randomized Trial | N = 3,417 | 96/100 | PMID 40544433 ↗ |
| Managing Overweight or Obesity: Can Once-Weekly Semaglutide Make a Real Difference? (What a 1,961-Person Study Found) In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. The New England journal of medicine • 2021-03-18 • Randomized Controlled Trial | N = 1,961 | 96/100 | PMID 33567185 ↗ |
| New Insights on Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2: What a 1,206-Participant Study Found Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes. The New England journal of medicine • 2025-08-14 • Phase III Randomized Trial | N = 1,206 | 96/100 | PMID 40544432 ↗ |
| Managing Obesity (STEP UP): Can Once-weekly semaglutide 7·2 mg Make a Real Difference? (What a 1,005-Person Study Found) Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile. The lancet. Diabetes & endocrinology • 2025-11-15 • Phase III Randomized Trial | N = 1,005 | 96/100 | PMID 40961952 ↗ |
| New Insights on Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin: What a 2,539-Participant Study Found In adults with obesity/overweight without type 2 diabetes, tirzepatide treatment was associated with improved β-cell function and insulin sensitivity, partly independent of weight reduction. Diabetes care • 2025-09-01 • Phase III Randomized Trial | N = 2,539 | 96/100 | PMID 40694530 ↗ |
Overweight Patient Community & “People Like Me” Threads
Filter Overweight community threads and patient logs by age, biological sex, dosage, and treatment duration.